Heterogeneity in Staphylococcus aureus Bacteraemia Clinical Trials Complicates Interpretation of Findings

Heather W. Dolby, Sarah A. Clifford, Ian F. Laurenson, Vance G. Fowler, Clark D. Russell

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

We systematically evaluated randomized-controlled trials (RCTs) for Staphylococcus aureus bacteremia (SAB). There was intertrial heterogeneity in cohort characteristics, including bacteremia source, complicated SAB, and comorbidities. Reporting of cohort characteristics was itself variable, including bacteremia source and illness severity. Selection bias was introduced by exclusion criteria relating to comorbidities, illness severity, infection types, and source control. Mortality was lower in RCT control arms compared with observational cohorts. Differences in outcome definitions impedes meta-analysis. These issues complicate the interpretation and application of SAB RCT results. The value of these trials should be maximized by a standardized approach to recruitment, definitions, and reporting.
Original languageEnglish
JournalThe Journal of Infectious Diseases
DOIs
Publication statusPublished - 27 May 2022

Fingerprint

Dive into the research topics of 'Heterogeneity in Staphylococcus aureus Bacteraemia Clinical Trials Complicates Interpretation of Findings'. Together they form a unique fingerprint.

Cite this